NEW YORK (GenomeWeb News) – J. Craig Venter today unveiled a new company called Human Longevity Inc. that will combine human genome, microbiome, and metabolome data coupled with clinical information to fuel development of new diagnostics, therapeutics, and stem cell treatments for diseases related to aging.

In a media briefing today, Venter said the company will "change the way medicine is practiced," and will spearhead "a shift to a more preventive, genomic-based medicine model" that can lead to longer, healthier lives and lower healthcare costs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.